diabetes glp 1 agonist Frontiers GLP-1 Agonists For Obesity In

This process was repeated 10,000 times to estimate the median and 95 % confidence interval (CIs) of the drug effects at each time point for each subgroup

Boots says

OR = 2.12 [0.696.53]), but there was substantial imprecision in the estimate for this comparison given information on eating disorders was only collected in one of the three survey waves and only a small proportion (4.2%) reported having received a diagnosis (Additional file 2: Table S1)

It is injected subcutaneously in the abdomen, thigh, or upper arm

Just make sure it's fat and not muscles getting depleted

CrossRef Stauffer VL, Sniadecki JL, Piezer KW, et al